Ceribell
- Industry
- Medical Technology
- Founded Year
- 2014
- Headquarters
- Sunnyvale, California
- Employee Count
- 281
Key People
- Xingjuan Chao - Co-founder and Chief Executive Officer
- David Stoffel - Chief Business Officer
- Baharan Kamousi - Senior Director of Data Science
- William Stadtlander - Chief Commercial Officer
- Heath Lukatch - Board Observer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in medical technology.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: The Ceribell System addresses a critical need for rapid seizure detection in acute care settings.
By enabling rapid diagnosis and continuous monitoring, the Ceribell System fulfills an urgent need in neurological care, potentially improving patient outcomes.
- Competition
-
Aspect: First mover
Summary: Ceribell is a pioneer in point-of-care EEG solutions, with limited direct competition.
While leading the market offers advantages, it also requires significant effort in educating potential customers and establishing new clinical protocols.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing and deploying the Ceribell System involves manageable technical complexities.
The integration of hardware and AI algorithms requires careful development and testing, but the company's expertise mitigates these challenges.
- Patent
-
Aspect: Strong
Summary: Ceribell holds a robust portfolio of patents covering its technology.
With 18 issued patents and 24 pending applications as of June 30, 2024, Ceribell has secured significant intellectual property protection for its innovations.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding to support its growth initiatives.
With total funding of $138 million, Ceribell is well-positioned to invest in research, development, and commercialization efforts.
- Regulatory
-
Aspect: 510k/PMA
Summary: The Ceribell System has received FDA 510(k) clearance for its intended use.
The FDA clearance validates the safety and efficacy of the Ceribell System, supporting its use in clinical settings.
Opportunity Rollup
- Odds of Success
- 3.2
- Peak Market Share
- 3.8
- Segment CAGR
- 4.9%
- Market Segment
- Neurology Devices
- Market Sub Segment
- Point-of-Care EEG Systems
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.19 |
| 2 | 0.57 |
| 3 | 1.33 |
| 4 | 2.66 |
| 5 | 3.80 |
Key Takeaway
Ceribell's innovative point-of-care EEG system addresses a critical clinical need, supported by a strong team and robust funding, positioning the company for significant growth in the neurology device market.